BOS-172722

N/A

Report date: 2026/03/16 20:01:47
NME

Base Information

Drug NameBOS-172722
Drug Alias NameBOS-172722CCT-289346
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity protein kinase TTK inhibitors
TargetsDual specificity protein kinase TTK
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHemostemix Asia
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoston Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A